Anti-interleukin (IL)-5 as a steroid-sparing agent in chronic eosinophilic pneumonia.
CONCLUSION: Our case report supports the potential use of anti-IL-5 therapy for remission of patients with CEP with recurrent relapses. Whether, it would also be an effective initial therapy might also be an area that deserves future investigation.
PMID: 30444149 [PubMed - as supplied by publisher]
Source: Journal of Asthma - Category: Respiratory Medicine Tags: J Asthma Source Type: research
More News: Allergy & Immunology | Asthma | Burns | Chronic Obstructive Pulmonary | Corticosteroid Therapy | Pneumonia | Study